Unicycive(US:UNCY) Globenewswireยท2025-10-12 12:52Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Unicycive [3]. - Investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's ability to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [5]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [6]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [7].